Listed by the USPTO as YU, TIAN NMN
Tech Center 1600 • Art Units: 1634 1637 1656 1681 1682 1699
This examiner grants 56% of resolved cases
YU, TIAN NMN is assigned to Tech Center 1600 and Art Unit 1634, with 92 resolved cases. The allowance rate is 56.5%, and the interview lift is 19.3%. The record provides a useful basis for prosecution planning, with the interview figure indicating a positive association that may support direct discussion of claim issues.
The median time to allowance is 1389 days. Applicants should account for that extended interval when managing filing, response, and continuation decisions. The listed companies are The Regents of the University of California, Guardant Health Inc., and Singular Genomics Systems Inc. The listed firms are HARNESS DICKEY (DETROIT), Sullivan & Worcester LLP, and WOLF GREENFIELD & SACKS, P.C. The figures should supplement, not replace, application-level analysis.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18620056 | METHODS FOR EARLY DETECTION OF CANCER | Non-Final OA | GUARDANT HEALTH, INC. |
| 18325759 | COMPOSITIONS AND METHODS FOR ENRICHING METHYLATED POLYNUCLEOTIDES | Non-Final OA | GUARDANT HEALTH, INC. |
| 18718585 | Single-Cell Epigenomic Profiling Using Droplet Fluidics and Hydrogels | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18169681 | EFFICIENT SCREENING LIBRARY PREPARATION | Non-Final OA | The Regents of the University of California |
| 17625687 | LIPID-MODIFIED OLIGONUCLEOTIDES AND METHODS OF USING THE SAME | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 17928452 | USE OF MICROVESICLE SIGNATURE FOR THE DIAGNOSIS AND TREATMENT OF KIDNEY TRANSPLANT REJECTION | Non-Final OA | The Brigham and Women's Hospital, Inc. |
| 18704416 | MANIPULATING AND DETECTING BIOLOGICAL SAMPLES | Non-Final OA | Singular Genomics Systems, Inc. |
| 17531488 | CONTACTLESS DETECTION OF AN ABERRANT CONDITION | Non-Final OA | Singular Genomics Systems, Inc. |
| 18499328 | DNA UNFOLDING USING A FREE-END TAG FLOW MODIFIER | Non-Final OA | Robert Bosch GmbH |
| 19449295 | DETECTING MUTATIONS AND PLOIDY IN CHROMOSOMAL SEGMENTS | Final Rejection | Natera, Inc. |
| 18279006 | METHODS FOR DETECTION OF DONOR-DERIVED CELL-FREE DNA IN TRANSPLANT RECIPIENTS OF MULTIPLE ORGANS | Final Rejection | Natera, Inc. |
| 18038454 | GRAPHENE-BASED BIOSENSOR AND DETECTION METHOD USING SAME | Non-Final OA | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY |
| 17260611 | POLYNUCLEOTIDE SYNTHESIS METHOD, KIT AND SYSTEM | Final Rejection | Oxford Nanopore Technologies PLC |
| 18154592 | RNA TEMPLATED LIGATION | Non-Final OA | 10x Genomics, Inc. |
| 17438038 | METHODS FOR USING SPATIAL ARRAYS FOR SINGLE CELL SEQUENCING | Final Rejection | 10x Genomics, Inc. |
| 18570947 | NUCLEIC ACID NANOPORE WITH ENHANCED SENSING FUNCTIONALITY | Non-Final OA | UCL BUSINESS LTD |
| 18677551 | ANALYSIS METHOD | Non-Final OA | Denso Corporation |
| 18718373 | BIOMARKERS TO DETECT AGGRESSIVE PROSTATE CANCER FROM INDOLENT FORMS AND TREATMENT THEREOF | Non-Final OA | The Johns Hopkins University |
| 18666949 | LINKAGE ASSAY | Non-Final OA | Bio-Rad Laboratories, Inc. |
| 18631875 | COMPOSITIONS AND METHODS FOR HLA HAPLOTYPE SEQUENCING | Non-Final OA | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY |
| 18275797 | MICRO RNA LIVER CANCER MARKERS AND USES THEREOF | Non-Final OA | THE CLEVELAND CLINIC FOUNDATION |
| 17373653 | cDNA SPIKE-IN CONTROL FOR SINGLE CELL ANALYSIS | Non-Final OA | Becton, Dickinson and Company |
| 18361763 | METHOD OF DETECTING MULTIPLE FORMS OF AN ANALYTE | Final Rejection | GEN-PROBE INCORPORATED |
| 17619154 | METHOD FOR DIAGNOSIS OF EARLY AGEING OF THE SKIN | Non-Final OA | L'OREAL |
| 17349041 | ASSESSING RISK WITH TOTAL CELL-FREE DNA | Non-Final OA | The Medical College of Wisconsin, Inc. |
| 18678592 | METHODS FOR DOUBLE-STRANDED SEQUENCING BY SYNTHESIS | Non-Final OA | ILLUMINA, INC. |
| 18515013 | REVERSIBLY CROSS-LINKED HYDROGELS, AND METHODS OF USING THE SAME FOR CLUSTER AMPLIFICATION | Final Rejection | Illumina, Inc. |
| 18298631 | METHODS AND COMPOSITIONS FOR RECOMBINASE-MEDIATED SELECTIVE CLEAVAGE OF NUCLEIC ACIDS | Non-Final OA | Illumina, Inc. |
| 17285362 | METHOD FOR MEASURING THE INFECTIVITY OF REPLICATION DEFECTIVE VIRAL VECTORS AND VIRUSES | Final Rejection | REGENXBIO Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy56.5% of resolved applications examined by Tian Nmn Yu were allowed (92 resolved cases), compared with 30.2% across Art Unit 1634 over the last five years.
This examiner's interview lift is +19.3 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Tian Nmn Yu took 1,389 days on average from filing to allowance.
Tian Nmn Yu examines applications in Art Unit 1634 in Tech Center 1600 (Biotechnology & Pharmaceuticals).